ArticleBiophotonics discovery2025
Enabling point of care optical diagnostics and treatment of oral lesions in resource-limited settings: Preclinical development and evaluation of a low-cost theranostic intraoral device for image-guided photodynamic therapy.
Article in Biophotonics discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Photodynamic therapy: A paradigm shift in overcoming drug‑resistant tuberculosis (Review).Molecular medicine reports · 2026Review
- Imaging protoporphyrin IX photoproduct accumulation as a dosimetry reporter for monitoring photodynamic therapy of oral cancer.Journal of biomedical optics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Significance: Oral squamous cell carcinoma (OSCC) is exceedingly prevalent and deadly in South Asia, especially the Indian subcontinent, affecting 15 out of every 100,000 people and claiming over 70,000 lives annually. This problem is further compounded by inadequate medical infrastructure for screening and cancer care, especially in rural areas. Aim: This study evaluates the design and assessment of a theranostic, low-cost, intraoral device to enable simultaneous multichannel optical imaging and photodynamic therapy (PDT) for detection and treatment of early oral cancer. Approach: The system's performance was assessed using buccal mucosal tissue phantoms containing protoporphyrin IX (PpIX), as well as OSCC phantoms photosensitized with 5-aminolevulinic acid (ALA)-induced PpIX. A murine xenograft model (Swiss nu/nu mice) implanted with TR146 OSCC cells was used to test the device's performance before and after ALA administration, as well as to evaluate photobleaching following light delivery (630nm, 100J/cm Result: The PpIX fluorescence signal demonstrated a linear correlation up to 50μM PpIX concentration. The degree of photobleaching increased with higher light doses up to 100J/cm Conclusion: A compact, handheld and low-cost intraoral device with dental camera form factor is able to carry out simultaneous multichannel white light and fluorescence imaging and image-guided PDT light delivery. The ability to quantify the extent of photobleaching as a dosimetry surrigate points to potential for real-time treatment monitoring with the same hardware.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.